RecruitingPHASE2, PHASE3NCT03373968
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Studying Duchenne muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Italfarmaco
- Intervention
- Givinostat(drug)
- Enrollment
- 206 enrolled
- Eligibility
- 7 years · MALE
- Timeline
- 2017 – 2029
Study locations (30)
- University of California - Davis Medical Center - Devis Physical Medicine & Rehabilitation, Sacramento, California, United States
- Rady Children's Hospital center - UCSD Department of Neuroscience, San Diego, California, United States
- Connecticut Children's Medical Center, Neurology Division, Hartford, Connecticut, United States
- Child Health Research Institute, Gainesville, Florida, United States
- MD Rare Disease Research, LLC, Atlanta, Georgia, United States
- University of Iowa Children's Hospital, Iowa City, Iowa, United States
- Washington University School of Medicine in St Louis Department of Neurology 660 S.Euclid Avenue, Campus Box 8111, St Louis, Missouri, United States
- Shriners Hospitals for Children, Portland, Oregon, United States
- The Children's Hospital of Philadelphia Colket Translational Research Building, Philadelphia, Pennsylvania, United States
- Virginia Commonwealth University Childrens Hospital of Richmond at, Richmond, Virginia, United States
- University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology, Leuven, Belgium
- Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN), Liège, Belgium
- Kinsmen Research Centre - Alberta Children's Hospital, Calgary, Alberta, Canada
- The University of British Columbia, Children's and Womens Health Centre of BC Branch, Vancouver, British Columbia, Canada
- Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada
- +15 more locations on ClinicalTrials.gov
Collaborators
Cromsource
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03373968 on ClinicalTrials.govOther trials for Duchenne muscular dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07332013Urinary Titin Biomarker in DMDChildren's Hospital of Philadelphia
- RECRUITINGNCT07092540The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular DystrophyUniversity of Rochester
- ENROLLING BY INVITATIONNANCT06887491The Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled TrialLokman Hekim University
- ACTIVE NOT RECRUITINGPHASE1NCT07347548A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsGrünenthal GmbH
- ENROLLING BY INVITATIONPHASE2NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT07287189Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsSatellos Bioscience, Inc.
- ENROLLING BY INVITATIONNCT07435116Duchenne Muscular Dystrophy and the Viscoelastic Properties of Upper Limb MusclesSanko University